Inhibition of GLUT1 expression has been shown to be facilitated by a group of anti-cancer therapies, including DT-13, Oridonin, and Oxymatrine [2,3,97], and by butyrate, which functions as a glycolysis inhibitor in CRC cells [98]. This evidence concerns the gene SLC2A1 and colorectal carcinoma.